ProfileGDS5678 / 1447704_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 57% 70% 69% 66% 59% 39% 59% 62% 65% 60% 67% 60% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6469360
GSM967853U87-EV human glioblastoma xenograft - Control 23.4520257
GSM967854U87-EV human glioblastoma xenograft - Control 34.4142470
GSM967855U87-EV human glioblastoma xenograft - Control 44.2986569
GSM967856U87-EV human glioblastoma xenograft - Control 53.9554766
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6462159
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.951839
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5228359
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7132362
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.874665
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5664560
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1075767
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6083260
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6321161